Document:

Exhibit

                                            

Exhibit 10.14

NON-EMPLOYEE DIRECTOR COMPENSATION
JANUARY 2019
The following is a description of non-employee director (“Director”) compensation for Fulton Financial Corporation (the “Company”), effective as of January 1, 2019.
The company pays cash fees to each Director on a quarterly basis as follows: 
		
	•
	    $70,000 annual cash retainer for all Directors.

		
	•
	    $30,000 additional annual cash retainer for the Lead Director.

		
	•
	$12,500 additional annual cash retainer for the Chair of all standing committees (Audit, Executive, Human Resources, Nominating and Corporate Governance, and Risk), except that if the Lead Director is also serving as chair of the Executive Committee, no cash retainer shall be paid for service as Chair of the Executive Committee.

		
	•
	No additional fees will be paid to a Director for attending a Board meeting or a standing committee meeting.

		
	•
	Cash fees currently paid to Directors serving on the Special Joint Board Compliance Committee (“SJBCC”) will continue to be paid to SJBCC members as follows:

•$1,000 per meeting attended by a SJBCC member.
•$12,500 annual cash fee retainer for the SJBCC Chair.
Each Director is granted an annual equity-based retainer award as follows:
		
	•
	 All equity-based awards are made under the Company’s 2011 Directors’ Equity Participation Plan, as amended (the “Plan”)

		
	•
	Directors elected at the Company’s annual meeting of shareholders shall be granted, as of the first of the month immediately following the meeting, under the Plan, an award of Director Restricted Stock Units (“DSU”) having an award value of $60,000, or such other value as determined by the Board.

		
	 
	A Director who joins the Board effective as of any other date shall be granted, as of such other date, a DSU award based on the award value of the most recent annual grant prorated to reflect the number of months (rounded up to the next whole month) remaining until the next annual meeting of shareholders. 

		
	•
	 The number of shares of common stock underlying a DSU award shall be determined by dividing the award value by the closing price of Company common stock on the principal stock exchange on the date of grant (rounded up to the nearest whole share). 

		
	•
	 Each equity-based grant will vest and be paid based on twelve months of service or in accordance with such other vesting schedule as determined by the Board, unless a Director has properly elected to defer payment and receipt of the common stock shares underlying such DSU award until they retire from the Company’s Board.

Directors are also entitled to reimbursement of costs and expenses incurred in connection with attending Company meetings and educational conferences.
Directors receive a Company paid $50,000.00 term life insurance policy, with the benefit payable upon death.Exhibit

Exhibit 10.15

FULTON FINANCIAL CORPORATION
DIRECTORS’ EQUITY PARTICIPATION PLAN, AS AMENDED
DIRECTOR STOCK UNIT AWARD AGREEMENT

Fulton Financial Corporation (the “Company”) hereby awards to the eligible Non-Employee Director named below (the “Participant”) the number of restricted stock units of the Company (the “Units”) in accordance with and subject to the terms and conditions of this Agreement together with the provisions of the Company’s 2011 Directors’ Equity Participation Plan (as it may be amended from time to time, the “Plan”), which Plan is incorporated herein by reference (all capitalized terms used herein having the meanings assigned in the Plan unless otherwise herein defined):
Name and Address of Participant:        [PARTICIPANT NAME]
[PARTICIPANT ADDRESS]

Number of Units Awarded:        [#DSU]

Relevant Dates:  The following dates are applicable for this Agreement:

Grant Date:                [GRANT DATE]
    
Lapse of Forfeiture Date:            The first anniversary of the Grant Date
    
    
Additional Terms and Conditions:

		
	1.
	Each Unit represents the right to receive one share of the Company's common stock, $2.50 par value per share (collectively, the “Shares”), upon the payment date following lapse of forfeiture.  The Units will be credited to the Participant in an account established for the Participant until the lapse of forfeiture event occurs; provided, however, that if the Participant makes a deferral election with respect to payment of any or all of the vested Units under the Company’s deferred compensation program for Non-Employee Directors, the terms of that deferral election shall apply to the payment of such deferred Units.  

		
	2.
	The right to receive the Shares underlying the Units will vest on the lapse of forfeiture date set forth above, or earlier upon the death, Disability or Retirement of the Participant, or departure from the Board resulting from a divestiture or a Change in Control, each as set forth in the Plan. If the Participant ceases to serve as a Director of the Company for any other reason before the lapse of forfeiture date, the unvested Units will be forfeited.  Payment of the Shares will occur promptly after vesting, unless the Participant has made a deferral election with respect to any vested Units, in which case the terms of that deferral election shall apply to the payment of such deferred Units. 

		
	3.
	This Award is subject to the terms of the Plan, the terms and conditions of which will govern this Award to the extent not otherwise provided in this Agreement.  A copy of the Plan is being delivered to the Participant with this Agreement.

		
	4.
	[Participant has elected to defer payment of the Shares underlying the Units, after the vesting of the right to receive the Shares the Participant shall be entitled to receive Dividend Equivalents, payable in shares of Common Stock, equal to the cash dividends the Company would have paid to such Participant had he or she been the holder of record of the Shares as of the close of business on the record date for the payment of the dividend] 

I hereby acknowledge receipt of this award agreement.

Signature: _______________________________________                  Date: ____________EX-10.1

 Exhibit 10.1 

EXECUTION VERSION 

AMENDMENT NO. 1 TO 

EMPLOYMENT AGREEMENT 
 THIS
AMENDMENT NO. 1 (this “Amendment”), is dated as of February 27, 2019 (the “Effective Date”) and amends that certain Employment Agreement (the “Agreement”) dated as of March 24, 2018
between Ronald A. Rittenmeyer (the “Executive”) and Tenet Healthcare Corporation (the “Company”). Capitalized terms used and not otherwise defined herein shall have the meanings assigned to them in the Agreement.

 RECITALS 

WHEREAS, the Company and the Executive previously entered into the Agreement; 

WHEREAS, pursuant to Section 16 of the Agreement, the Agreement may be amended or waived only with the prior written consent of
the Company and Executive; and 
 WHEREAS, the Company and Executive desire to amend the Agreement as set forth herein, effective as
of the Effective Date. 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby
acknowledged, the parties hereto, intending to be legally bound, hereby agree as follows: 
 1. The first sentence of Section 1 of the
Agreement is hereby amended and restated as follows: 
 “The Company agrees to continue to employ the Executive pursuant to the terms of
this Agreement, and the Executive agrees to continue to be so employed commencing as of the Effective Date and ending on June 30, 2021 (the “Term”).” 

2. To reflect that nothing in this Amendment shall be interpreted to modify or alter any rights and obligations the Company or the Executive
have with respect to the previously granted RSUs and Restricted Cash as provided in the Agreement prior to this Amendment, including the vesting schedule, the first sentence of each of Sections 3(c) and 3(d) of the Agreement is hereby amended to
delete the phrase “as of the conclusion of the Term” and insert in lieu thereof “on February 28, 2020”. 
 3. A new
Section 3(h) is added as follows: 
 “(h) Additional Equity Awards. In consideration of the Executive entering into the
Amendment and as an inducement to continue Executive’s employment with the Company through the conclusion of the Term, on February 27, 2019 the Company will grant an additional award of restricted stock units (collectively with the RSUs
set forth in Section 3(c) hereof, the “RSUs”) pursuant to the Sixth Amended and Restated Tenet Healthcare 2008 Stock Incentive Plan (the “Plan”) with an aggregate grant date fair value equal to $16,000,000,
which shall vest in nine (9) equal quarterly installments beginning on June 30, 2019 until fully vested as of the conclusion of the Term (each such quarterly date beginning on June 30, 2019 and concluding on June 30, 2021, a
“Vesting Date”), subject to the Executive’s continued employment with the Company through each Vesting Date, unless vesting is accelerated in accordance with Section 4 below. All other terms and
conditions of such awards shall be governed by the terms and conditions of the Plan and the applicable award agreement, provided that such terms and conditions shall not be inconsistent with the terms of this Agreement.” 

 4. A new Section 4(g) is hereby added as follows: 

“(h) Services Agreement. Notwithstanding anything to the contrary in the Agreement, following the conclusion of the Term or a
termination of Executive’s employment by the Company without Cause or by Executive for Good Reason, the Company and the Executive shall enter into a services agreement mutually acceptable to the parties (the “Consulting
Agreement”), pursuant to which the Company will engage the Executive as a consultant in a manner that constitutes a “separation from service” for purposes of Code Section 409A. The Consulting Agreement shall provide for the
Executive’s provision of consulting services during the two (2)-year period following the conclusion of the Term or a termination of Executive’s employment by the Company without Cause or by Executive for Good Reason (the
“Consulting Period”). The Consulting Agreement shall provide that the Executive will remain an employee of the Company for tax-purposes in an advisory position reporting to the Chief Executive
Officer of the Company and perform consulting and advisory services as reasonably requested by the Chief Executive Officer and the Board for a period of time not to exceed eight (8) days per month. During the Consulting Period, the Executive
shall continue to be treated as one of the Company’s most senior executives and will remain entitled to receive customary Company benefits and perquisites on the same basis as other senior executives of the Company. The Consulting Agreement
shall provide the Executive with an annual retainer of $750,000 for each year during the Consulting Period, payable in accordance with the Company’s payroll practices as then in effect, and the Executive shall remain eligible to participate in
the Company’s health and welfare benefits on the same basis as other active senior executives during the Consulting Period. In addition, during and following the Consulting Period, the Executive shall remain subject to restrictive covenants no
less favorable to the Company than those set forth in Section 7 of this Agreement. 
 5. Section 7(a) is hereby
amended to add a concluding sentence as follows: 
 “Nothing contained in this Agreement shall be construed to prohibit the Executive
from reporting possible violations of federal or state law or regulation to any governmental agency or regulatory body or making other disclosures that are protected under any whistleblower provisions of federal or state law or regulation, or from
filing a charge with or participating in any investigation or proceeding conducted by any governmental agency or regulatory body.” 

6. The first clause of the first sentence of Section 7(b) is hereby amended and restated as follows: 

“(b) (i) During the Employment Period and for a period of two (2) years following the Termination Date (the “Restricted
Period”).” 
 7. This Amendment shall only serve to amend and modify the Agreement to the extent specifically provided herein.
All terms, conditions, provisions and references of and to the Agreement which are not specifically modified, amended and/or waived herein shall remain 

  
 2 

 
in full force and effect and shall not be altered by any provisions herein contained. As of the Effective Date, this Amendment shall supersede and preempt any prior understandings, agreements or
representations by or among the parties, written or oral, which may have related to the subject matter of this Amendment in any way other than the Agreement, the agreements referenced herein or in the Agreement, and any agreement which by its terms
continues beyond the Executive’s termination of employment. 
 8. This Amendment shall not be amended, modified or supplemented except
by a written instrument signed by the parties hereto. The failure of a party to insist on strict adherence to any term of this Amendment on any occasion shall not be considered a waiver or deprive that party of the right thereafter to insist upon
strict adherence to that term or any other term of this Amendment. No waiver of any provision of this Amendment shall be construed as a waiver of any other provision of this Amendment. Any waiver must be in writing. 

9. This Amendment shall inure to the benefit of, and be binding upon, the successors, administrators, heirs, legal representatives and assigns
of Executive, and the successors and assigns of the Company. 
 10. This Amendment may be executed and delivered (including by facsimile,
“pdf” or other electronic transmission) in any number of counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same agreement. 

[Signature Page Follows] 

  
 3 

 IN WITNESS WHEREOF, the parties hereto have executed this Amendment as of the
Effective Date. 
  

			
	TENET HEALTHCARE CORPORATION
		
	By:	 	 /s/ Audrey Andrews

	Name:	 	Audrey Andrews
	Title:	 	Senior Vice President and General Counsel
	Date:	 	February 27, 2019

  

	
	RONALD A. RITTENMEYER
	
	 /s/ Ronald A. Rittenmeyer

	Date: February 27, 2019

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00292-of-00352.parquet"}]]